FDA expands pediatric use of Bristol's HIV drug Sustiva

05/6/2013 | Drug Store News · RTT News

The FDA approved Bristol-Myers Squibb's Sustiva, or efavirenz, to treat HIV-1 patients ages 3 months to 3 years who weigh at least 7.7 pounds. The approval covers sprinkle administration when swallowing a capsule or tablet isn't possible. The drug was evaluated in three open-label trials involving 182 patients.

View Full Article in:

Drug Store News · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA